Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. reports news about its life sciences automation business for microbial quality-control testing in healthcare manufacturing. The company develops and sells the Growth Direct platform, proprietary consumables, LIMS connectivity, software and services used to automate microbial analysis for pharmaceuticals, medical devices and personal care products.
Recurring updates include financial results and guidance, Growth Direct system placements and validations, customer orders from global biopharma and CDMO manufacturers, and company participation in healthcare investor conferences. News also covers equity compensation actions and Nasdaq-related employment inducement grants tied to its public-company governance.
Rapid Micro Biosystems (Nasdaq: RPID) reported first quarter 2026 revenue of $8.0 million, up 11.1% year-over-year, with recurring revenue of $5.1 million, or 63% of total. The company placed six new Growth Direct systems and completed five validations.
Product revenue grew 36% while service revenue declined 21.9%. Gross margin was 4.6%, with product and consumable gross margin percentages improving by 15 and 33 points, respectively. Net loss widened to $14.3 million ($0.31 per share). The company advanced its MilliporeSigma collaboration and reaffirmed 2026 guidance of $37.0–$41.0 million in revenue, 30–38 system placements, and gross margin of about 20%.
Rapid Micro Biosystems (Nasdaq: RPID) will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026. Management will host a live webcast conference call at 4:30 p.m. ET the same day. The live audio webcast is available on the company website and will be archived for replay.
Rapid Micro Biosystems (Nasdaq: RPID) reported record Q4 2025 revenue of $11.3M (+37% YoY) and full year 2025 revenue of $33.6M (+20% YoY). The company placed 28 Growth Direct systems in 2025 and now has 190 cumulative placements with 155 validated.
Net loss was $47.1M for 2025 and cash plus short-term investments totaled $39.0M. For 2026 the company forecasts revenue of $37.0M–$41.0M, 30–38 system placements, and gross margins of ~20%.
Rapid Micro Biosystems (Nasdaq: RPID) announced a follow-on multi-system order from Samsung Biologics on March 12, 2026 to expand deployment of the Growth Direct platform.
The order strengthens the companies' partnership and supports Samsung's expansion of automated microbial quality control across its manufacturing network, aiming for faster results, greater accuracy, and improved data integrity.
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the KeyBanc Capital Markets Healthcare Forum with a virtual Q&A on March 17, 2026 at 11:15 a.m. ET. A live webcast will be available on the company's investor relations site and will be archived for later replay.
Rapid Micro Biosystems (Nasdaq: RPID) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026 at 10:30 a.m. Eastern Time. The presentation will be webcast live and archived for later replay.
According to the company, the live webcast will be available on its investor relations website and accessible for on-demand viewing after the event.
Rapid Micro Biosystems (Nasdaq: RPID) will release fourth quarter and full year 2025 financial results before market open on March 12, 2026.
Management will host a live webcast conference call at 8:30 a.m. ET on March 12, 2026, accessible via the company website; the webcast will be archived for replay after the event.
Rapid Micro Biosystems (Nasdaq: RPID) announced inducement equity awards granted February 2, 2026, to three newly hired employees.
The company granted 205,000 RSUs and 168,000 stock options under its Inducement Plan, with options priced at $4.19 per share and standard time-based vesting schedules.
The awards were approved by a majority of independent directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Rapid Micro Biosystems (Nasdaq: RPID) reported preliminary unaudited revenue results for Q4 and full‑year 2025. Q4 2025 revenue ≈ $11.3M, up ~37% year‑over‑year, including placement of 16 new Growth Direct systems and validation of three customer systems.
Full‑year 2025 revenue is expected to be ≈ $33.6M, up ~20% year‑over‑year, with recurring revenue ≈ $17.8M, up ~15% year‑over‑year. The company placed 28 new Growth Direct systems in 2025 and has cumulatively placed 190 systems with 155 validated.
Results are preliminary and unaudited; final audited results and a webcast with 2026 outlook will be released in Q1 2026. The company will present at the J.P. Morgan Healthcare Conference on Jan 15, 2026.
Rapid Micro Biosystems (Nasdaq: RPID) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company investor relations website and will be archived for replay after the event.